Orchard Therapeutics Launched
News May 04, 2016
UCL Business, the technology transfer company of UCL, and venture capital firm F-Prime Capital Partners have launched Orchard Therapeutics, a biotechnology company specialising in gene therapies for life threatening rare childhood diseases.
Orchard Therapeutics has secured £21 million investment led by F-Prime to support the development of gene therapy treatments for a range of diseases.
As part of its launch, Orchard announced formal partnerships with UCL, Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), University of California Los Angeles (UCLA), The University of Manchester, Boston Children’s Hospital for the development of these transformative gene therapies.
Orchard’s lead programme is for the treatment of the rare and fatal disorder called severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID), sometimes referred to as “bubble baby” syndrome in the press. Children with the disorder must be protected from any infections due to their highly fragile immune system.
In a first-in-man clinical study, global leaders in the field at UCL/GOSH and UCLA have shown significant immune reconstitution and 100% survival in 32 patients treated, as of March 2016.
Orchard’s financing has been led by F-Prime Capital, with support from UCLB and additional participation from the UCL Technology Fund.
Cengiz Tarhan, Managing Director of UCLB, said:
“We are very excited to see UCL’s breakthrough treatments move forward in a commercial environment in a way that will benefit patients globally. The formation of Orchard represents the culmination of decades of research at UCL and its partners and we are delighted to be able to work with F-Prime Capital to launch Orchard.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.